Aplastic anemia

International Journal of Hematology

Volumn 82, Issue 5, 2005, Pages 408-411

  Kojima, Seiji ^a   Frickhofen, Norbert ^b   Deeg, H Joachim ^c   Okamoto, Shinichiro ^d   Marsh, Judith ^e   Teramura, Masanao ^f   Bacigalupo, Andrea ^g   Mizoguchi, Hideaki ^h  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c Fred Hutchinson Cancer Research Center   (United States)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF GENOA   (Italy)

^h JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

Antithymocyte globulin; Aplastic anemia; Bone marrow transplantation; Cyclosporine; Immunosuppressive therapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 3; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RITUXIMAB; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE LEUKEMIA; AGE DISTRIBUTION; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DONOR SELECTION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LOW DRUG DOSE; MESENCHYMAL STEM CELL; NEUTROPHIL COUNT; PATIENT SELECTION; PROPHYLAXIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT TANDEM REPEAT; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION; CONSENSUS DEVELOPMENT; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METHODOLOGY; PANCYTOPENIA; PATHOLOGY; T LYMPHOCYTE;

ANEMIA, APLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELLS; PANCYTOPENIA; T-LYMPHOCYTES;

EID: 33646447868     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05138     Document Type: Conference Paper

References (25)

1. Marsh JC, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol. 2003;123:782-801.
2. Bacigalupo A, Podestà M, Raffo MR, et al. Lack of in vitro colony formation and myelosuppressive activity in patients with sevre aplastic anemia after autologous hematologic reconstitution. Exp Hematol. 1980;8:795-801.
3. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996;87:4149-4157.
4. Bacigalupo A, Valle M, Podestà M, et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol. 2005;33:819-827.
5. Ascensao J, Pahwa R, Kagan W, Hansen J, Moore M, Good R. Aplastic anemia: evidence for an immunological mechanism. Lancet. 1976;1:669-671.
6. Young NS. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med. 1997;126:166-168.
7. Podestà M, Piaggio G, Frassoni F, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91:1959-1965.
8. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69-80.
9. Hill RS, Petersen FB, Storb R, et al. Mixed hematologic chimaerism after allogeneic marrow transplant for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood. 1986;67:811-816.
10. Schrezenmeier H, Bacigalupo A. Aplastic Anemia. Pathophysiology and treatment 2000. In: McCann SR, Passweg Jr, Storb R, Deeg HJ, eds HLA-Identical Sibling Bone Marrow Transplantation to Treat Severe Aplastic Anemia. 2000;230-257.
11. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941-949.
12. Dulley FL, Vigorito AC, Aranha FJ, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33:9-13.
13. Pierga JY, Socie G, Gluckman E, et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol. 1994;30:55-58.
14. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus Cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96:1690-1697.
15. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208-215.
16. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799-803.
17. Young N, Barrett J. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367-3377.
18. Schrezenmeier H, Bacigalupo A. Guidelines 2000 in Aplastic Anemia. Pathophysiology and treatment. 2000;230-257.
19. Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193-201.
20. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931-1934.
21. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107:330-334.
22. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J of Haematol. 1993;85:371-377.
23. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009-1013.
24. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119:1075-1082.
25. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up at a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236-1242.